Skip to main content

Table 4 CircN4BP2L2, CA125 and HE4 expression levels according to histology, type and stage; ROC AUC, sensitivity, specificity, and significant difference in type II EOC vs. benign and normal cohorts

From: Diagnostic value of circN4BP2L2 in type I and type II epithelial ovarian cancer

Type II EOC cohort

Benign cohort

Normal cohort

 

Median (range)

Median (range)

ROC AUC

(95% CI)

Sen

Spe

P-value

Median (range)

ROC AUC

(95% CI)

Sen

Spe

P-value

CircN4BP2L2

19 (1–84)

82 (1–367)

0.88 (0.84–0.91)

93%

71%

< 0.01*

82 (11–439)

0.91 (0.88–0.94)

80%

87%

< 0.01*

 Early-stage a

24 (1–74)

 

0.85 (0.79–0.92)

88%

67%

< 0.01*

 

0.89 (0.83–0.95)

83%

77%

< 0.01*

 Late-stage a

19 (2–84)

 

0.88 (0.84–0.92)

94%

69%

< 0.01*

 

0.92 (0.89–0.95)

83%

87%

< 0.01*

CA125

233 (18–5801)

48 (13–373)

0.72 (0.65–0.79)

72%

32%

< 0.01*

29 (4–69)

0.84 (0.79–0.89)

72%

58%

< 0.01*

 Early-stage a

30 (18–560)

 

0.46 (0.31–0.60)

46%

32%

0.49

 

0.68 (0.55–0.80)

46%

58%

< 0.01*

 Late-stage a

398 (22–5801)

 

0.79 (0.72–0.86)

79%

32%

< 0.01*

 

0.89 (0.84–0.94)

79%

58%

< 0.01*

HE4

79 (32–438)

46 (12–237)

0.79 (0.73–0.84)

75%

76%

< 0.01*

44 (7–235)

0.78 (073–0.84)

75%

82%

< 0.01*

 Early-stage a

88 (34–231)

 

0.77 (0.68–0.87)

71%

76%

< 0.01*

 

0.75 (0.65–0.85)

71%

82%

< 0.01*

 Late-stage a

78 (32–438)

 

0.79 (0.74–0.85)

77%

76%

< 0.01*

 

0.79 (0.73–0.85)

77%

82%

< 0.01*

  1. a According to International Federation of Gynecology and Obstetrics staging
  2. Abbreviations: EOC, epithelial ovarian cancer; ROC, receiver operating characteristic curve; AUC, area under curve; 95% CI, 95% confidence interval; Sen, sensitivity; Spe, specificity